January 29, 2020
AstraZeneca has agreed to sell the global commercial rights to
Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone
fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril,
hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs).
The agreement excludes the rights
in the US and India, which were previously divested, and in Japan, which will
be retained by AstraZeneca.
Atnahs will make an upfront
payment of US$350 million to AstraZeneca. AstraZeneca may also receive future
sales-contingent payments of up to US$40 million between 2020 and 2022.
Latham & Watkins advised
Atnahs in the transaction, with a deal team led by London corporate partner
Robbie McLaren, with New York counsel Eliot Choy and London associates Frances
Stocks Allen, Emily Cridland, Samantha Peacock, Natalie Brown, and Mihail Krepchev.